Tonix Pharmaceuticals Presents Phase 1 Data On TNX-4800, Long-Acting Human mAb Targeting OspA Of Borrelia Burgdorferi At World Vaccine Congress Washington 2026

Tonix Pharmaceuticals Holding Corp. presented Phase 1 data on TNX-4800, a long-acting human monoclonal antibody targeting the outer surface protein A of Borrelia burgdorferi, at the World Vaccine Congress Washington 2026. The conference took place from March 30 to April 2, 2026, in Washington, D.C. Additionally, the company showcased TNX-801, a horsepox live virus vaccine candidate for smallpox and mpox prevention. Dr. Christopher Cooper moderated a panel on modular antigen-delivery systems for novel vaccines.